First Momentum Ventures invests in Atlas Bio
Funding Provisional 86% confidence first seen
Tech.eu reports that First Momentum Ventures led a previously undisclosed $2.5M pre-Seed round in Swiss biotech Atlas Bio, alongside LEA Partners, as part of a broader $12.5M total funding effort that included a $10M Seed led by Creandum. The coverage describes Atlas Bio’s platform as building a foundational AI model for in silico clinical trials to reduce reliance on animal testing and compress Phase II trial timelines. This matters because the reported investment supports a shift toward AI-driven, human-relevant evidence generation in drug development.
The deal
Atlas Bio $12.5 million Other · announced 27 Oct 2026
Investors Creandum First Momentum Ventures LEA Partners
Deal terms as reported in the coverage below.
Decision brief
- What changed
- Atlas Bio, a Swiss biotech, disclosed a $12.5 million funding effort, including a previously undisclosed $2.5 million pre-Seed round led by First Momentum Ventures and a $10 million Seed led by Creandum. The company says it is building a foundational AI model for in silico clinical trials trained on roughly 2 million RNA readouts from human tissue.
- Why it matters
- For leaders in life sciences and adjacent AI markets, this funding indicates investor support for AI systems positioned as alternatives or complements to animal testing and parts of early clinical development. If Atlas Bio’s approach proves usable in practice, it could affect R&D timelines, evidence-generation workflows, and partnership opportunities around preclinical and Phase II decision support, but the coverage only supports that capital has been committed to pursue this model.
- Evidence
- The claim is supported by a single Tech.eu report stating that Atlas Bio emerged from stealth with $12.5 million in total funding, including the $2.5 million pre-Seed led by First Momentum Ventures and a $10 million Seed led by Creandum. Because the coverage comes from one outlet and appears based on company funding disclosure, the financing event is directly reported but independently corroborated technical and commercial validation is limited in the provided material.
- What remains uncertain
- The coverage does not verify Atlas Bio’s model performance, regulatory acceptance, customer traction, or whether 12-week virtual simulations will be accepted in actual drug-development workflows. It also does not establish how much of the claimed reduction in animal testing or Phase II compression is demonstrated today versus planned.
- Monitor next
- Watch for disclosed pilot results, pharma partnerships, or regulatory-facing validation showing whether Atlas Bio’s in silico trial platform is being adopted beyond the funding announcement.
Analytical support, not advice — assumptions and open questions stated above.